Bicara Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Bicara Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BCAX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0002023658

Board of directors

Follow this board

Chief executives

Claire Mazumdar · Chief Executive Officer
Dates unknown
Ryan Cohlhepp · President, COO & Interim CEO Interim
Dates unknown

Director election results

Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 34 other boards.

Network of Bicara Therapeutics Inc.'s board connections Janux Therapeutics Inc. Janux Therapeutics Inc... Parabilis Medicines Inc. Parabilis Medicines In... Septerna Inc. Septerna Inc. Tyra Biosciences Inc. Tyra Biosciences Inc. ARS Pharmaceuticals Inc. ARS Pharmaceuticals In... Acrivon Therapeutics Inc. Acrivon Therapeutics I... Acumen Pharmaceuticals Inc. Acumen Pharmaceuticals... Artiva Biotherapeutics Inc. Artiva Biotherapeutics... Black Diamond Therapeutics Inc. Black Diamond Therapeu... Climb Bio Inc. Climb Bio Inc. Evommune Inc. Evommune Inc. Freenome Inc. Freenome Inc. Hemab Therapeutics Holdings Inc. Hemab Therapeutics Hol... Jade Biosciences Inc. Jade Biosciences Inc. LENZ Therapeutics Inc. LENZ Therapeutics Inc. Mineralys Therapeutics Inc. Mineralys Therapeutics... Jake Simson Jake Simson Peter Kolchinsky Peter Kolchinsky Rajeev M. Shah Rajeev M. Shah Bicara Therapeutics Inc.
Shared director Other board Same sector +18 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$4,800,000
1 purchase by 1 insider
Sold, last 12 months
$13,541,391
72 sales by 5 insiders
Date Insider Transaction Shares Price Value
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Option exercise +17,500 $3.79 $66,322
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Open-market sale −14,058 $22.77 $320,053
Sep 8, 2026 Ryan Cohlhepp Director, Officer (President, COO & Interim CEO) Open-market sale −3,442 $23.43 $80,663
Aug 10, 2026 Ryan Cohlhepp Director, Officer (President and COO) Option exercise +18,750 $3.79 $71,059
Aug 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Option exercise +10,000 $3.79 $37,898
Aug 10, 2026 Hyep Ivan Officer (Chief Financial Officer) Option exercise +12,500 $3.79 $47,373
Aug 10, 2026 Ryan Cohlhepp Director, Officer (President and COO) Open-market sale −18,750 $27.98 $524,533
Aug 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −10,000 $27.98 $279,750
Aug 10, 2026 Hyep Ivan Officer (Chief Financial Officer) Open-market sale −12,500 $27.97 $349,591
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Option exercise +10,000 $3.79 $37,898
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −9,972 $28.42 $283,367
Jul 10, 2026 Claire Mazumdar Director, Officer (Chief Executive Officer) Open-market sale −28 $29.68 $831
Jul 9, 2026 Ryan Cohlhepp Director, Officer (President and COO) Open-market sale −536 $29.00 $15,544
Jul 8, 2026 Hyep Ivan Officer (Chief Financial Officer) Option exercise +12,500 $3.79 $47,373
Jul 8, 2026 Ryan Cohlhepp Director, Officer (President and COO) Option exercise +18,750 $3.79 $71,059

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.